| Citation: |
LI Jin, DONG Jingtao, DONG Zhenbo, ZHANG Yun, LI Zhiyuan, WANG Jieying. Effect of peginterferon α-2a combined with entecavir on related factors in patients with chronic hepatitis B[J]. Journal of Clinical Medicine in Practice, 2023, 27(2): 92-96. DOI: 10.7619/jcmp.20222866
|
To explore the effect of peginterferon α-2a combined with entecavir on hepatitis B virus DNA (HBV-DNA), immune function and levels of inflammatory factors in patients with chronic hepatitis B.
A total of 220 patients with chronic hepatitis B were randomly divided into study group and control group, with 110 cases in each group. The control group was orally given entecavir tablets, while the study group was given peginterferon α-2a by subcutaneous injection on the basis of the control group. Both groups were treated continuously for 6 months. The levels of HBV-DNA, immune function indexes (CD4+, CD19+, CD8+) and inflammatory factors [interferon-γ (IFN-γ), macrophage colony-stimulating factor (M-CSF), CXC motif chemokine receptor 4 (CXCR4), stromal cell-derived factor 1 (SDF-1)] were compared between two groups.
After treatment, the level of HBV-DNA decreased significantly in both groups, and the level of HBV-DNA in the study group was significantly lower than that in the control group (P < 0.01). After treatment, the level of CD4+ increased significantly while the levels of CD19+ and CD8+ decreased significantly in both groups, and the level of CD4+ in the study group was significantly higher than that in the control group, while the levels of CD19+ and CD8+ were significantly lower than those in the control group (P < 0.01). After treatment, the levels of IFN-γ, M-CSF, CXCR4 and SDF-1 decreased significantly in both groups, and the levels of IFN-γ, M-CSF, CXCR4 and SDF-1 in the study group were significantly lower than those in the control group (P < 0.01). Difference values of IFN-γ, M-CSF, CXCR4 and SDF-1 levels before and after treatment in the study group were significantly higher than those in the control group (P < 0.01).
Peginterferon α-2a combined with entecavir is effective and safe in the treatment of patients with chronic hepatitis B, which can reduce the HBV-DNA level, enhance the immunity of patients, and inhibit the levels of inflammatory factors.
| [1] |
牛卫理, 王永素, 吴清山, 等. 加用干扰素治疗核苷(酸)类似物经治的HBsAg低水平的慢性乙型肝炎患者获得临床治愈的效果观察[J]. 临床肝胆病杂志, 2021, 37(8): 1793-1797. doi: 10.3969/j.issn.1001-5256.2021.08.010
|
| [2] |
魏超, 江鸿, 邓先桂, 等. 茵芪三黄解毒汤联合常规西医治疗慢性乙型肝炎肝胆湿热证患者的疗效观察[J]. 实用临床医药杂志, 2021, 25(9): 37-40, 51. https://www.cnki.com.cn/Article/CJFDTOTAL-XYZL202109009.htm
|
| [3] |
李福华, 刘雯. 恩替卡韦联合苦黄注射液对ALT < 2×ULN的HBeAg阴性慢性乙型肝炎患者凝血-纤溶功能、免疫炎症及肝脏硬度的影响[J]. 现代中西医结合杂志, 2019, 28(15): 1634-1637. doi: 10.3969/j.issn.1008-8849.2019.15.010
|
| [4] |
郑志恒, 李维筠, 回振宇, 等. 聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙型肝炎患者疗效及血清Pygo2和GP73水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 19-22. doi: 10.3969/j.issn.1672-5069.2021.01.006
|
| [5] |
中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2010年版)[J]. 实用肝脏病杂志, 2011, 14(2): 81-89. doi: 10.3969/j.issn.1672-5069.2011.02.001
|
| [6] |
顾桥. 柴胡桂枝干姜汤联合恩替卡韦治疗慢性乙型肝炎的临床研究[D]. 南宁: 广西中医药大学, 2018.
|
| [7] |
胡晓, 毛德文, 牙程玉, 等. 慢性乙型肝炎发病机制及治疗的研究进展[J]. 实用中医内科杂志, 2021, 35(4): 10-12. https://www.cnki.com.cn/Article/CJFDTOTAL-SYZY202104003.htm
|
| [8] |
阿力木江·毛拉艾沙, 布力布力·马那甫, 古丽加孜依拉, 等. 不同用药方案治疗HBeAg阳性慢性乙型肝炎的效果及对血清IFN-γ、IL-10的影响[J]. 中国医药导报, 2017, 14(5): 137-140, 156. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201705036.htm
|
| [9] |
GSCHWANTLER M, LAFERL H, VOGEL W, et al. Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy: final results of the Austrian PegHope study[J]. Wien Klin Wochenschr, 2018, 130(1/2): 54-61.
|
| [10] |
JINDAL A, VYAS A K, KUMAR D, et al. Higher efficacy of pegylated interferon-α2b add-on therapy in hepatitis B envelope antigen-positive chronic hepatitis B patients on tenofovir monotherapy[J]. Hepatol Res, 2018, 48(6): 451-458.
|
| [11] |
杨荟玉, 孙爱民, 程豪为, 等. 国产恩替卡韦胶囊治疗慢性乙型肝炎的随机、双盲、阳性药物平行对照临床研究[J]. 郑州大学学报: 医学版, 2017, 52(5): 633-637. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYK201705029.htm
|
| [12] |
张金艳, 马洪德, 杨汝磊. 恩替卡韦分散片治疗对高病毒载量慢性乙肝患者的T细胞亚群及血清脂联素、IFN-γ、IL-2水平的影响[J]. 罕少疾病杂志, 2022, 29(1): 60-62. https://www.cnki.com.cn/Article/CJFDTOTAL-HSJB202201027.htm
|
| [13] |
BOGLIONE L, CARITI G, GHISETTI V, et al. Extended duration of treatment with peginterferon Alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: a retrospective analysis[J]. J Med Virol, 2018, 90(6): 1047-1052.
|
| [14] |
HSU C W, SU W W, LEE C M, et al. Phase IV randomized clinical study: Peginterferon Alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B[J]. Journal of the Formosan Medical Association, 2018, 117(7): 588-597.
|
| [15] |
栗红江, 胡素玲, 刘洋, 等. 慢性乙型病毒性肝炎患者血清25-羟基维生素D3水平与外周血T淋巴细胞亚群相关性分析[J]. 临床军医杂志, 2022, 50(2): 205-207, 210. https://www.cnki.com.cn/Article/CJFDTOTAL-JYGZ202202027.htm
|
| [16] |
常晋芳. PEG-IFNα-2a联合恩替卡韦治疗慢性乙型肝炎的效果及对患者免疫功能的影响[J]. 临床医学研究与实践, 2021, 6(29): 62-64. https://www.cnki.com.cn/Article/CJFDTOTAL-YLYS202129020.htm
|
| [17] |
康晓, 俞力, 王蕾, 等. 聚乙二醇干扰素α-2a联合恩替卡韦治疗老年慢性乙型肝炎的效果及影响因素[J]. 中国临床保健杂志, 2020, 23(1): 89-93. https://www.cnki.com.cn/Article/CJFDTOTAL-LZBJ202001023.htm
|
| [18] |
牛兴杰, 刘志慧, 崔凤梅, 等. 相关炎症指标预测慢性乙型肝炎患者肝纤维化程度的价值[J]. 中华医院感染学杂志, 2020, 30(5): 703-708. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY202005016.htm
|
| 1. |
王姝琪. 以埃索美拉唑和奥美拉唑为主的三联疗法治疗幽门螺杆菌阳性胃溃疡的比较. 中国实用乡村医生杂志. 2022(04): 29-32 .
| |
| 2. |
齐义. 序贯药物方案与四联疗法对Hp阳性慢性胃炎活动期患者Hp根除率及复发的影响. 齐齐哈尔医学院学报. 2021(02): 127-129 .
| |
| 3. |
殷久勇. 序贯疗法与四联疗法治疗幽门螺杆菌感染性胃溃疡的临床对照研究. 江西医药. 2021(10): 1735-1738 .
| |
| 4. |
张曼，高炳霞，齐颖，张盈盈. 依卡倍特钠联合常规四联疗法对幽门螺杆菌阳性慢性萎缩性胃炎的疗效观察. 现代消化及介入诊疗. 2020(01): 76-79 .
| |
| 5. |
刘小辉. 四联疗法对内镜黏膜下剥离术后幽门螺杆菌感染患者炎症因子水平及愈合质量的影响. 黑龙江医学. 2020(02): 210-212 .
| |
| 6. |
钟文洲，林松挺，李春芸. 十天序贯疗法与标准三联疗法治疗幽门螺杆菌感染的疗效及对患者昼夜胃内p H的影响. 中国临床研究. 2019(01): 46-49 .
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: